207_Combined course Presentations

First page Table of contents Previous page 1227 Next page Last page

RTOG 0522: C-RT ± cetuximab for stage III-IV HNSCC

• 940 pts with stage III-IV HNSCC of the larynx and pharynx • No significant differences in PFS or OS • Triplet patients had higher rates of grade 3-4 mucositis and skin reactions